Business Description
GlaxoSmithKline Pharmaceuticals Ltd
ISIN : INE159A01016
Share Class Description:
BOM:500660: Shs DematerialisedCompare
Compare
Traded in other countries / regions
GLAXO.India IPO Date
1991-03-01Description
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives most of its revenue from India.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 80.53 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 453.17 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 13.11 | |||||
| Beneish M-Score | -2.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.3 | |||||
| 3-Year EBITDA Growth Rate | 31.9 | |||||
| 3-Year EPS without NRI Growth Rate | 10.4 | |||||
| 3-Year FCF Growth Rate | 9.8 | |||||
| 3-Year Book Growth Rate | -1.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.25 | |||||
| 9-Day RSI | 52.75 | |||||
| 14-Day RSI | 47.25 | |||||
| 6-1 Month Momentum % | 34.11 | |||||
| 12-1 Month Momentum % | 58.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.71 | |||||
| Quick Ratio | 1.34 | |||||
| Cash Ratio | 1.18 | |||||
| Days Inventory | 144.27 | |||||
| Days Sales Outstanding | 20.91 | |||||
| Days Payable | 128.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.65 | |||||
| Dividend Payout Ratio | 0.86 | |||||
| 3-Year Dividend Growth Rate | 14.5 | |||||
| Forward Dividend Yield % | 1.65 | |||||
| 5-Year Yield-on-Cost % | 3.39 | |||||
| Shareholder Yield % | 1.72 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.14 | |||||
| Operating Margin % | 23.02 | |||||
| Net Margin % | 15.97 | |||||
| FCF Margin % | 13.29 | |||||
| ROE % | 33.51 | |||||
| ROA % | 16.51 | |||||
| ROIC % | 41.47 | |||||
| ROC (Joel Greenblatt) % | 232.16 | |||||
| ROCE % | 40 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 59.67 | |||||
| PE Ratio without NRI | 50.09 | |||||
| Shiller PE Ratio | 49.83 | |||||
| Price-to-Owner-Earnings | 58.24 | |||||
| PEG Ratio | 5.63 | |||||
| PS Ratio | 9.53 | |||||
| PB Ratio | 20.5 | |||||
| Price-to-Tangible-Book | 21.78 | |||||
| Price-to-Free-Cash-Flow | 71.72 | |||||
| Price-to-Operating-Cash-Flow | 65.2 | |||||
| EV-to-EBIT | 42.33 | |||||
| EV-to-EBITDA | 38.73 | |||||
| EV-to-Revenue | 9.43 | |||||
| EV-to-FCF | 68.06 | |||||
| Price-to-Projected-FCF | 7.4 | |||||
| Price-to-Graham-Number | 7.08 | |||||
| Price-to-Net-Current-Asset-Value | 42.81 | |||||
| Earnings Yield (Greenblatt) % | 2.36 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 10.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 33,113.63 | ||
| EPS (TTM) (₹) | 31.23 | ||
| Beta | 0.36 | ||
| Volatility % | 34.59 | ||
| 14-Day RSI | 47.25 | ||
| 14-Day ATR (₹) | 62.647411 | ||
| 20-Day SMA (₹) | 1928.6575 | ||
| 12-1 Month Momentum % | 58.38 | ||
| 52-Week Range (₹) | 1228 - 2649.95 | ||
| Shares Outstanding (Mil) | 169.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
GlaxoSmithKline Pharmaceuticals Ltd Frequently Asked Questions
What is GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660)'s stock price today?
The current price of BOM:500660 is ₹1942.65. The 52 week high of BOM:500660 is ₹2649.95 and 52 week low is ₹1228.00.
When is next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660)?
The next earnings date of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is .
Does GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) pay dividends? If so, how much?
The Dividend Yield %  of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is 1.65% (As of Today), Highest Dividend Payout Ratio of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) was 1.41. The lowest was 0.64. And the median was 0.84. The  Forward Dividend Yield % of GlaxoSmithKline Pharmaceuticals Ltd(BOM:500660) is 1.65%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers